The present invention relates to compounds of formula (I). The compounds maybe used to antagonise the Stimulator of Interferon Genes (STING) protein and may thereby treat liver fibrosis, fatty liver disease, non-alcoholic steatohepatitis (NASH), pulmonary fibrosis, lupus, sepsis, rheumatoid arthritis (RA), type I diabetes, STING-associated vasculopathy with onset in infancy (SAVI), Aicardi-Goutieres syndrome (AGS), familial chilblain lupus (FCL), systemic lupus erythematosus (SLE), retinal vasculopathy, neuroinflammation, systemic inflammatory response syndrome, pancreatitis, cardiovascular disease, renal fibrosis, stroke and age-related macular degeneration (AMD).

This disclosure relates generally to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives for the treatment of conditions associated with cannabinoid receptor.

A light emitting element includes a first electrode, a second electrode disposed on the first electrode, and an emission part disposed between the first electrode and the second electrode and including a first emission layer and a second emission layer disposed on the first emission layer, the first emission layer may include a first host, and a first dopant, and the second emission layer may include a hole transport host different from the first host, an electron transport host, and a second dopant. A first hole mobility of the first host may be in a range of about 5.0×10.sup.−6 cm.sup.2/Vs to about 1.0×10.sup.−3 cm.sup.2/Vs, a second hole mobility of a host mixture including the hole transport host and the electron transport host may be in a range of about 1.0×10.sup.−6 cm.sup.2/Vs to about 1.0×10.sup.−4 cm.sup.2/Vs, and the first hole mobility may be larger than the second hole mobility.

A light emitting element includes a first electrode, a second electrode disposed on the first electrode, and an emission part disposed between the first electrode and the second electrode and including a first emission layer and a second emission layer disposed on the first emission layer, the first emission layer may include a first host, and a first dopant, and the second emission layer may include a hole transport host different from the first host, an electron transport host, and a second dopant. A first hole mobility of the first host may be in a range of about 5.0×10.sup.−6 cm.sup.2/Vs to about 1.0×10.sup.−3 cm.sup.2/Vs, a second hole mobility of a host mixture including the hole transport host and the electron transport host may be in a range of about 1.0×10.sup.−6 cm.sup.2/Vs to about 1.0×10.sup.−4 cm.sup.2/Vs, and the first hole mobility may be larger than the second hole mobility.

Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.

Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.

This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

A method of performing a chemical reaction includes reacting a compound selected from the group consisting of an organohalide and an organo-pseudohalide, and a protected organoboronic acid represented by formula (I) in a reaction mixture:
R.sup.1—B-T  (I);
where R.sup.1 represents an organic group, T represents a conformationally rigid protecting group, and B represents boron having sp.sup.3 hybridization. When unprotected, the corresponding organoboronic acid is unstable by the boronic acid neat stability test. The reaction mixture further includes a base having a pK.sub.B of at least 1 and a palladium catalyst. The method further includes forming a cross-coupled product in the reaction mixture.